Trials Sponsors Conditions Drugs Pricing

Conditions

Adult Brain Malignant Hemangiopericytoma Adult Fibrosarcoma Adult Leiomyosarcoma Adult Malignant Meningioma Adult Rhabdomyosarcoma Chondrosarcoma

Study Arms (1)

ifosfamide

EXPERIMENTAL

ifosfamide

Drug: ifosfamide

Interventions

ifosfamideDrug

ifosfamide

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically proven recurrent or unresectable: * Malignant meningioma * Intracranial hemangiopericytoma * Primary central nervous system sarcoma, including: * Fibrosarcoma * Rhabdomyosarcoma * Chondrosarcoma * Leiomyosarcoma * Measurable or evaluable disease on CT or MRI scan * Persistent disease following biopsy or incomplete resection OR * Recurrent disease following complete resection * No benign meningioma * No prior or current systemic sarcoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-2 Life expectancy: * Not specified Hematopoietic: * WBC at least 3,000/mm\^3 * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Not specified Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No myocardial infarction within the past 3 months * No active angina * No unstable heart rhythms * No congestive heart failure Other: * HIV negative * No allergy to study drugs * No serious concurrent medical or psychiatric illness * No uncontrolled peptic ulcer disease * No prior malignancy within past 5 years except adequately treated: * Basal or squamous cell carcinoma of the skin * Carcinoma in situ of the cervix * Not pregnant or nursing * Effective contraception required of fertile patients PRIOR CONCURRENT THERAPY: * Recovered from toxic effects of prior therapy and/or from postoperative complications Biologic therapy: * Not specified Chemotherapy: * No prior ifosfamide * No other concurrent chemotherapy Endocrine therapy: * No concurrent hormonal therapy (except estrogen replacement therapy) * Corticosteroids allowed if dose is stable or decreasing Radiotherapy: * At least 4 weeks since prior radiotherapy * Progressive disease following radiation required * No concurrent radiotherapy Surgery: * See Disease Characteristics

Sponsors & Collaborators

Eastern Cooperative Oncology Group
Research networkcollaborator
National Cancer Institute (NCI)
NIHcollaborator
SWOG Cancer Research Network

Study Sites (70)

CCOP - Scottsdale Oncology Program

Scottsdale, Arizona, 85259-5404, United States

City of Hope Comprehensive Cancer Center

Duarte, California, 91010-3000, United States

Veterans Affairs Medical Center - Palo Alto

Palo Alto, California, 94304-1290, United States

Stanford University Medical Center

Stanford, California, 94305-5216, United States

CCOP - Colorado Cancer Research Program, Incorporated

Denver, Colorado, 80224, United States

CCOP - Christiana Care Health Services

Newark, Delaware, 19713, United States

Veterans Affairs Medical Center - Gainesville

MeSH Terms

Conditions

ChondrosarcomaFibrosarcomaLeiomyosarcomaRhabdomyosarcomaMeningioma

Interventions

Ifosfamide

Condition Hierarchy (Ancestors)

Neoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcomaNeoplasms, Fibrous TissueNeoplasms, Muscle TissueMyosarcoma

Study Officials

Leslie McAllister, MD
Neurological Clinic
STUDY CHAIR
Lynn G. Feun, MD
University of Miami Sylvester Comprehensive Cancer Center
STUDY CHAIR

Enrollment

7 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: NETWORK
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 1, 1999

First Posted

January 27, 2003

Study Start

July 1998

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Study Arms (1)

ifosfamide

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (70)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Study Arms (1)

ifosfamide

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (70)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations